key: cord-0688124-wwdc8d3g authors: Tang, Fang; Zhang, Xiaoshuai; Zhang, Bicheng; Zhu, Bo; Wang, Jun title: A nomogram prediction of outcome in patients with COVID‐19 based on individual characteristics incorporating immune response‐related indicators date: 2021-08-27 journal: J Med Virol DOI: 10.1002/jmv.27275 sha: 9a955071b43c42c1b271c2465c58c2dea18ce086 doc_id: 688124 cord_uid: wwdc8d3g INTRODUCTION: The coronavirus disease 2019 (COVID‐19) has quickly become a global threat to public health, and it is difficult to predict severe patients and their prognosis. Here, we intended developing effective models for the late identification of patients at disease progression and outcome. METHODS: A total of 197 patients were included with a 20‐day median follow‐up time. We first developed a nomogram for disease severity discrimination, then created a prognostic nomogram for severe patients. RESULTS: In total, 40.6% of patients were severe and 59.4% were non‐severe. The multivariate logistic analysis indicated that IgG, neutrophil‐to‐lymphocyte ratio (NLR), lactate dehydrogenase, platelet, albumin, and blood urea nitrogen were significant factors associated with the severity of COVID‐19. Using immune response phenotyping based on NLR and IgG level, the logistic model showed patients with the NLR(hi)IgG(hi) phenotype are most likely to have severe disease, especially compared to those with the NLR(lo)IgG(lo) phenotype. The C‐indices of the two discriminative nomograms were 0.86 and 0.87, respectively, which indicated sufficient discriminative power. As for predicting clinical outcomes for severe patients, IgG, NLR, age, lactate dehydrogenase, platelet, monocytes, and procalcitonin were significant predictors. The prognosis of severe patients with the NLR(hi)IgG(hi) phenotype was significantly worse than the NLR(lo)IgG(hi) group. The two prognostic nomograms also showed good performance in estimating the risk of progression. CONCLUSIONS: The present nomogram models are useful to identify COVID‐19 patients with disease progression based on individual characteristics and immune response‐related indicators. Patients at high risk for severe illness and poor outcomes from COVID‐19 should be managed with intensive supportive care and appropriate therapeutic strategies. Since December 2019, coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has quickly spread to every continent except Antarctica and become a global threat to public health. 1, 2 The number of patients with severe disease and death is persistently high outside of China. Although the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) have significantly higher case fatality rates than COVID-19, COVID-19 is responsible for more fatal cases because the underlying SARS-CoV-2 virus spread more easily among people by droplets produced by coughing, sneezing, or talking, leading to greater numbers of cases across the world. 3 A majority of COVID-19 patients have a mild disease course, but a subgroup of patients will experience continuing disease deterioration. 4, 5 It is urgent to identify the critical risk factors that help predict the progression and outcome of this disease. The early identification of disease deterioration and poor outcomes will help develop appropriate and necessary supportive care and reduce mortality. Previous investigations had linked clinical characteristics such as older age, multiple morbidities, and supplemental oxygen at the time of hospitalization to severe COVID-19 disease at admission. [6] [7] [8] Some circulating factors, including C-reactive protein (CRP), interleukin-6, and procalcitonin (PCT), have been found to have a prognostic value in the severity of COVID-19 or the mechanical ventilation. [9] [10] [11] [12] Basically, a single risk factor failed to accurately estimate the severity and clinical outcome of individual COVID-19 patients. Moreover, a recently identified early prediction model only focused on the common laboratory variables. [13] [14] [15] [16] Following SARS-CoV-2 infection, a high viral load and overexuberant host immune response involving innate and acquired immunity, simultaneously contribute to the pathogenesis of COVID-19 and organ injury. 4, 6, 17 The baseline NLR has been identified as an independent risk factor for critical illness in COVID-19 patients. 18 Our previous findings suggest that COVID-19 severity is associated with increased IgG response following confirmed SARS-CoV-2 infection, and an immune response phenotyping based on two immune-related indicators IgG and NLR is useful to discriminate severe and nonsevere patients. 18 Therefore, we attempt to establish immune response factors-based and factors-weighted accurate outcome risk estimation models, to help clinicians to select appropriate therapeutic decisions. All included patients with COVID-19 had been admitted to the Renmin Hospital of Wuhan University, from January 13, 2020 to March 10, 2020. The confirmed diagnosis of COVID-19 was defined as a positive result by using real-time reverse-transcriptase polymerase chain reaction (RT-PCR) detection for routine nasal and pharyngeal swab specimens or anti-SARS-CoV-2 antibody assay. There were five patients with negative RT-PCR results who had typical chest computed tomography findings or clinical symptoms. The percentage of laboratory-confirmed COVID-19 patients in patients admitted to the hospital was 88.7%. Finally, a total of 197 laboratory-confirmed COVID-19 patients were included in this study. Serum samples were collected at the convalescent phase for further analysis. We retrospectively evaluated their anti-SARS-CoV-2 antibody response, clinical disease severity at the time of IgG detection, and clinical outcome. In the present study, mild and moderate cases were recognized as "non-severe" cases, whereas severe and critical cases were "severe" cases according to a baseline clinical We employed quantiles as cut-off values to categorize blood urea nitrogen (BUN), PCT, and monocyte (MONO) as nonlinear effects on the outcome were found in these variables. In addition, we proposed a combined immune response phenotype by summarizing NLR and IgG into a four-level variable (NLR_IgG) using medians as cut-offs, including high NLR-high IgG (NLR hi IgG hi ), high NLR-low IgG (NLR hi IgG lo ), low NLR-high IgG (NLR lo IgG hi ), and low NLR-low IgG (NLR lo IgG lo ). For disease discrimination, we used severe or nonsevere as a binary dependent variable. Furthermore, for the prediction of prognosis for the subgroup of severe patients in the Cox analysis, disease progression was viewed as the endpoint. Patients with disease progression consisted of patients requiring intensive care unit care and dead patients. Baseline characteristics of the COVID-19 patient were assessed by severe group and non-severe group and described as medians and interquartile range (IQR) for continuous variables and proportions for categorical variables. We compared the baseline characteristics using the Mann-Whitney test for continuous variables and the χ 2 test for categorical variables. In the present study, we first constructed two nomograms based on a logistic model with baseline information to discriminate the severe and non-severe patients. One nomogram used NLR and IgG as independent factors, and the other employed a combined immune response phenotype based on NLR and IgG levels as predictors. Nomograms based on Cox proportional hazard model in predicting the prognosis for the severe patients were built subsequently. Similar to the logistic models, we conducted two nomograms using NLR and IgG as independent predictors and the combined phenotype NLR_IgG, respectively. Each nomogram gives a score for each of the variables, and the total points of one patient are obtained by summing up the scores of all the variables. Then, the predicted probability can be estimated with a vertical line dropping down from the total points. Variables including baseline characteristics were analyzed by multivariate regression analysis. The final models were determined incorporating both clinical hypothesis and statistical methods. Our preliminary analyses have suggested that NLR and IgG might be associated with COVID-19 severity and could be used to further predict their clinical outcome. Age has also been identified as an independent predictor in COVID-19. Therefore, the variable selection was conducted by stepwise selection technique with Akaike information criterion keeping age, IgG, and NLR in the model. Both discrimination and calibration ability of this nomogram was evaluated using Harrell's C-index and a calibration plot, respectively. 20 A calibration plot was generated to validate the agreement between the probability predicted by the nomogram and the observed proportions. The bootstrap technique was employed to estimate the bias-corrected measures to validate the nomograms internally. Bias-corrected C-index and calibration were calculated by subjecting the nomogram to 1000 bootstrap resamples. All statistical analyses were performed using R version 3.6.1 with the "rms" and "forestplot" package. No non-severe patients progressed to severe disease. Two nomograms were established based on a logistic model with the baseline information to discriminate the severe and non-severe patients. Figure 1 shows the results of the logistic model using IgG and NLR as independent factors. The multivariate logistic analysis indicated that IgG, NLR, LDH, PLT, ALB, and BUN were significant factors associated with the severity of COVID-19 ( Figure 1B) . Age is not significant in the final model while it still contributes to the severity of discrimination. Figure 1A All patients were followed after the time of IgG analysis to establish the prognosis prediction model. As no non-severe patients progressed to severe disease, we therefore only predicted the prognosis of the severe patients. Figure The prognosis of severe patients with NLR hi IgG hi phenotype is significantly worse than the NLR lo IgG hi group. A nomogram has been developed as an early quantitative predictor tool for discrimination between severe and non-severe patients using data from a single center or multiple centers with small sample size. 15 Another nomogram generated by Gong et al. 16 was used to predict patients at risk of progressed illness with a high AUC in the training and validation cohorts. Using fatal outcome as an endpoint, Chen et al. 13 found that older age, coronary heart disease, cerebrovascular disease, dyspnea, and high level of PCT and aspartate aminotransferase were independent risk factors associated with poor outcomes. Older age, certain comorbidities, dyspnea, lower presented and associated with a more severe viral infection. 21, 22 Recent data indicated that the NLR, an indicator of innate immunity, was identified as a powerful predictive and prognostic factor for severe COVID-19. 18 Previous data showed severe SARS was associated with more robust serological responses including early ALB, albumin; BUN, blood urea nitrogen; CI, confidence interval; HR, hazard ratio; IgG, immunoglobulin G; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; PLT, platelet seroconversion and higher IgG levels. 23 Our previous findings suggest that COVID-19 severity is associated with increased IgG response, and an immune response phenotyping based on two immune-related indicators IgG and NLR is useful to discriminate between severe and non-severe patients. 24 High NLR was also Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia A novel coronavirus from patients with pneumonia in China The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical characteristics of 82 cases of death from COVID-19 Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Diabetes is a risk factor for the progression and prognosis of COVID-19 Predictors for severe COVID-19 infection Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early Prognostic value of C-reactive protein in patients with COVID-19 Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China Critical patients with coronavirus disease 2019: risk factors and outcome nomogram Prediction for progression risk in patients with COVID-19 pneumonia: the CALL Score A tool to early predict severe coronavirus disease 2019 (COVID-19): a multicenter study using the risk nomogram in Wuhan and Guangdong, China Pathological findings of COVID-19 associated with acute respiratory distress syndrome Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7) Evaluating the yield of medical tests Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients SARS immunity and vaccination Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome A nomogram prediction of outcome in patients with COVID-19 based on individual characteristics incorporating immune response-related indicators We acknowledge all healthcare workers involved in the diagnosis and treatment of patients in Eastern Campus, Renmin Hospital of Wuhan University. This study was funded by the Fundamental Research Funds for the Central Universities, China (No. 2042020kfxg07). The authors declare that there are no conflict of interests. Zhu prepared the data. Xiaoshuai Zhang and Fang Tang analyzed the data. Jun Wang, Xiaoshuai Zhang, and Fang Tang wrote the paper. All authors have read and approved the final manuscript. The data that support the findings of this study are available from the corresponding author upon reasonable request. http://orcid.org/0000-0002-4378-594XJun Wang https://orcid.org/0000-0003-3941-2507